Inactive Instrument

Surface Oncology, Inc.

Equities

SURF

US86877M2098

Biotechnology & Medical Research

Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase

August 24, 2022 at 04:31 pm EDT

CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 2:30 p.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Surface Oncology website at https://investors.surfaceoncology.com/. In addition, a replay of the webcast will be available on the company’s website following the presentation.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com

Source: Surface Oncology, Inc.

2022 GlobeNewswire, Inc., source Press Releases

Latest news about Surface Oncology, Inc.

Surface Oncology, Inc.(NasdaqCM:SURF) dropped from S&P TMI Index	23-09-13	CI
Surface Oncology, Inc.(NasdaqCM:SURF) dropped from S&P Global BMI Index	23-09-13	CI
Coherus BioSciences Completes Acquisition of Surface Oncology	23-09-08	MT
Surface Oncology, Inc. Announces Director Changes	23-09-08	CI
Surface Oncology, Inc.(NasdaqCM:SURF) dropped from NASDAQ Composite Index	23-09-08	CI
Coherus BioSciences, Inc. completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.	23-09-07	CI
Surface Oncology Says Takeover by Coherus BioSciences Gets Backing From ISS, Glass Lewis	23-08-31	MT
Surface Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Index	23-06-23	CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index	23-06-23	CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell 3000E Index	23-06-23	CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell 3000E Value Index	23-06-23	CI
North American Morning Briefing : Investors Eye -2-	23-06-21	DJ
Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3	23-06-20	MT
Baird Downgrades Surface Oncology to Neutral From Outperform, Cuts Price Target to $1 From $6	23-06-20	MT
HC Wainwright Downgrades Surface Oncology to Neutral From Buy, Price Target is $5	23-06-20	MT
Top Midday Decliners	23-06-16	MT
Sector Update: Health Care Stocks Gain Premarket Friday	23-06-16	MT
Sector Update: Health Care	23-06-16	MT
Coherus BioSciences to Purchase Surface Oncology in All-Stock Deal	23-06-16	MT
Transcript : Coherus BioSciences, Inc., Surface Oncology, Inc. - M&A Call	23-06-16
Coherus BioSciences to Acquire Surface Oncology in Stock-For-Stock Transaction Valued at $65 Million	23-06-16	MT
Coherus BioSciences, Inc. entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.	23-06-15	CI
Surface Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Surface Oncology Presents New Preclinical Data on SRF114 at the AACR Annual Meeting 2023	23-04-18	CI

Chart Surface Oncology, Inc.

Duration

Period

More charts

Company Profile

Surface Oncology, Inc. is a clinical-stage, immuno-oncology company, which is focused on developing immunotherapies that target the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company's pipeline includes two wholly owned clinical-stage programs targeting IL-27 (SRF388) and SRF114 a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8. In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The Company's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-2.32%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.33%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.50%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-25.01%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.29%	11.68B
MEDPACE HOLDINGS, INC.	+20.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.50%	11.15B

Other Biotechnology & Medical Research